Whole-Body Photobiomodulation for Motor and Cognitive Changes in Parkinson's Disease
NCT ID: NCT07271927
Last Updated: 2025-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
15 participants
INTERVENTIONAL
2025-02-12
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transcranial Photobiomodulation as a Therapy for Patients With Parkinson's Disease: Relationship Between Pain and Brain Functional Connectivity (FBM)
NCT05959772
Transcranial Photobiomodulation With Patients With Parkinson's Disease
NCT06729125
Sublingual Photobiomodulation in Parkinson's Disease
NCT04028817
Revitalize Cognition: Near Infrared Stimulation in Parkinson Patients
NCT06688357
Effect of WB-EMS on Parkinson's Disease
NCT04878679
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Parkinson
Participants received whole-body PBM therapy once daily (20 minutes per session), three times per week, for approximately 10 weeks, totaling 30 sessions.
Photobiomodulation
Participants received whole-body PBM therapy over approximately 10 weeks (three sessions per week, once daily, 20 minutes per session), with each session using a randomly selected wavelength of either 660 nm, 850 nm, or 940 nm (±20%).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Photobiomodulation
Participants received whole-body PBM therapy over approximately 10 weeks (three sessions per week, once daily, 20 minutes per session), with each session using a randomly selected wavelength of either 660 nm, 850 nm, or 940 nm (±20%).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adults aged 40 years or older
* Individuals able to walk independently
Exclusion Criteria
* Patients with dementia other than Parkinson's disease dementia
* Individuals with implanted medical or other electronic devices
* Individuals with severe neuropsychiatric disorders
* Individuals treated for alcohol dependence within 6 months prior to screening
* Individuals with a history of suicide attempts
* Individuals with a history of seizures
* Individuals experiencing dyspnea while sitting at rest
* Individuals with visual impairment preventing them from reading ordinary text even with corrective lenses
* Individuals with hearing impairment preventing them from understanding conversation even with a hearing aid
* Individuals who have participated in two or more clinical trials in the same year or in another clinical trial within the past 6 months
* Women and men of childbearing potential who are planning pregnancy during the trial or who do not agree to use appropriate contraceptive methods
* Pregnant or breastfeeding women
* Individuals deemed medically inappropriate for participation by the principal investigator or study staff based on clinically significant findings not otherwise specified above
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pusan National University Yangsan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yong-il Shin
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pusan National University Yangsan Hospital
Yangsan, Gyeongsangnam-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23-2024-005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.